DHODH and childhood malignant neoplasm: Targeting pyrimidine ribonucleotide synthesis, specifically by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH), has recently shown promising preclinical results in different types of cancers including pediatric cancers [[7], [8], [9], [10]].